On June 5, 2024, Eli Lilly and Company announced that Anat Ashkenazi resigned as Executive Vice President of the Company to pursue another career opportunity outside of the pharmaceutical industry. Ms. Ashkenazi will continue to serve at full capacity in her role and as a member of the Company?s Executive Committee through July 2024. An internal and external search for Ms. Ashkenazi?s successor is underway.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
909 USD | +0.86% |
|
+2.60% | +55.95% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.95% | 811B | |
+43.62% | 640B | |
-6.98% | 353B | |
+19.08% | 333B | |
+9.05% | 302B | |
+16.30% | 246B | |
+2.41% | 225B | |
+12.47% | 218B | |
+8.91% | 168B | |
-3.44% | 155B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly and Company Announces Resignation of Anat Ashkenazi as Executive Vice President